TL;DR
Digital cognitive assessments that target Alzheimer’s-disease-vulnerable systems can detect earlier functional change and strengthen plasma-biomarker prognosis.
Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.
The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of Alzheimer's disease in older adults, and suggest depression and other neuropsychiatric symptoms may be predictors of AD's progression during its "preclinical" phase.
Participants with healthier patterns of brain blood flow and oxygen regulation had lower amyloid burden, reinforcing the idea that vascular function may be linked to Alzheimer's-related changes.
A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate.
Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
